Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus by Welsch, Christoph et al.
Genome Biology 2008, 9:R16
Open Access 2008 Welsch et al. Volume 9, Issue 1, Article R16 Research
Molecular basis of telaprevir resistance due to V36 and T54 
mutations in the NS3-4A protease of the hepatitis C virus
Christoph Welsch¤*†‡, Francisco S Domingues¤*, Simone Susser†‡, 
Iris Antes*, Christoph Hartmann*, Gabriele Mayr*, Andreas Schlicker*, 
Christoph Sarrazin†‡, Mario Albrecht*, Stefan Zeuzem†‡ and 
Thomas Lengauer*
Addresses: *Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrücken, 
Germany. †Department of Internal Medicine I, Johann Wolfgang Goethe University Hospital, 60590 Frankfurt/Main, Germany. ‡Department 
of Internal Medicine II, Saarland University Hospital, 66421 Homburg/Saar, Germany. 
¤ These authors contributed equally to this work.
Correspondence: Christoph Welsch. Email: christophwelsch@gmx.net
© 2008 Welsch et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Molecular basis of Telaprevir resistance <p>Structural analysis of the inhibitor Telaprevir (VX-950) of the hepatitis C virus (HCV) protease NS3-4A shows that mutations at V36  and/or T54 result in impaired interaction with VX-950, explaining the development of viral breakthrough variants.</p>
Abstract
Background: The inhibitor telaprevir (VX-950) of the hepatitis C virus (HCV) protease NS3-4A
has been tested in a recent phase 1b clinical trial in patients infected with HCV genotype 1. This
trial revealed residue mutations that confer varying degrees of drug resistance. In particular, two
protease positions with the mutations V36A/G/L/M and T54A/S were associated with low to
medium levels of drug resistance during viral breakthrough, together with only an intermediate
reduction of viral replication fitness. These mutations are located in the protein interior and far
away from the ligand binding pocket.
Results: Based on the available experimental structures of NS3-4A, we analyze the binding mode
of different ligands. We also investigate the binding mode of VX-950 by protein-ligand docking. A
network of non-covalent interactions between amino acids of the protease structure and the
interacting ligands is analyzed to discover possible mechanisms of drug resistance. We describe the
potential impact of V36 and T54 mutants on the side chain and backbone conformations and on
the non-covalent residue interactions. We propose possible explanations for their effects on the
antiviral efficacy of drugs and viral fitness. Molecular dynamics simulations of T54A/S mutants and
rotamer analysis of V36A/G/L/M side chains support our interpretations. Experimental data using
an HCV V36G replicon assay corroborate our findings.
Conclusion: T54 mutants are expected to interfere with the catalytic triad and with the ligand
binding site of the protease. Thus, the T54 mutants are assumed to affect the viral replication
efficacy to a larger degree than V36 mutants. Mutations at V36 and/or T54 result in impaired
interaction of the protease residues with the VX-950 cyclopropyl group, which explains the
development of viral breakthrough variants.
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Background
More than 170 million people worldwide are chronically
infected with the hepatitis C virus (HCV). Combination ther-
apy with pegylated interferon-α plus ribavirin shows sus-
tained virologic response rates of approximately 50% in HCV
genotype 1 infected patients [1-3], which emphasizes the need
for new antiviral drugs. The ser i n e  p r o t e a s e  N S 3 - 4 A  i s  a
promising drug target for specific antiviral treatment. HCV
genotypes exhibit about 80% sequence identity in NS3-4A,
with highly conserved key residues [4]. NS3-4A is bifunc-
tional, possessing a protease as well as a helicase domain.
Especially the protease domain is a target for rational drug
design [5-8]. The serine protease has a chymotrypsin fold,
which consists of the amino-terminal 181 amino acids of NS3.
The three catalytic residues H57, D81 and S139 are located in
a crevice between the two protease β-barrels [9-11]. The num-
bering used in the following is according to the structure
1DY8 [12] taken from the Protein Data Bank (PDB) [13,14].
The central region of NS4A is buried almost completely inside
NS3 and serves as a cofactor for proper folding of NS3 [9].
The binding pocket of the protease is shallow, non-polar, and
rather difficult to target. Therefore, the development of
potent protease inhibitors has been a challenging task in the
past. This is reflected by the variety of rational drug design
approaches and drug candidates tested so far, for example,
protease substrate or product analogs, serine-trap inhibitors,
tripeptide inhibitors and de-novo  peptidomimetics [6,15].
Data for drug resistance and antiviral efficacy have been pub-
lished for the protease inhibitors BILN-2061 (ciluprevir)
[16,17], VX-950 (telaprevir) [18-20], and SCH 503034
(boceprevir) [21,22].
VX-950 is a tetrapeptidic compound with α-ketoamide as
active-site binding motif, covalently bound to S139 [23-25].
Figure 1 shows the chemical structure of VX-950 in compari-
son with other ligands. Strong antiviral efficacy for VX-950
was demonstrated in vivo during a phase 1b clinical trial, with
an HCV RNA decline above 3 log after treatment duration of
only 24 hours [18]. As observed with other specific antiviral
agents, the treatment efficacy diminished over time, due to
the selection of drug-resistant viral variants. Mutations that
confer drug resistance to VX-950 were detected independ-
ently in different patients within two weeks of treatment.
They have been found at four different sites: V36, T54, R155
and A156 [18,19,26]. In vitro drug resistance was quantified
by enzymatic, inhibitory concentration 50% (IC50) values
[19,26-28]. Viral fitness and corresponding replication effica-
cies were measured by HCV RNA levels [19,26-28].
R155 and A156 are localized in the binding pocket of the pro-
tease NS3-4A. A156 interferes directly with protease inhibitor
binding and leads to high-level drug resistance [19]. An exten-
sive analysis of HCV quasispecies revealed single mutants at
positions V36, T54 and R155, and double-mutants at V36/
R155 in all breakthrough patients investigated [19]. V36, T54
and R155 mutants confer low- to medium-level drug resist-
ance, and an inverse relationship between in vivo viral fitness
and drug resistance was observed [19]. The mutations are
associated with an intermediate reduction in viral replication
efficacy. Mutations at position V36 conferred low-level resist-
ance to VX-950 with a mean IC50 value of 226 nM and an IC50
range of 110 nM to 444 nM, compared with the HCV reference
strain, genotype 1a. Interestingly, the T54S mutant was asso-
ciated with low-level resistance and a mean IC50 value of 120
nM, while the T54A mutant showed a higher level of resist-
ance with a mean IC50 value of 749 nM. In vitro IC50 data and
corresponding IC50 fold changes in resistance over the HCV
genotype 1a reference strain are summarized for VX-950 in
Table 1 [19,26,28]. Molecular mechanisms leading to drug
resistance at R155 and A156 have been investigated [19,20],
whereas the reason for drug resistance mutants at V36 and
T54 is still unknown. The present work investigates the
molecular basis for VX-950 resistance at V36 and T54.
Results
The following sections describe the results of the analysis of
the HCV protease structure of NS3-4A and the different lig-
and interaction modes using alternative experimental struc-
ture models. The ligand binding mode of the inhibitor VX-
950 was investigated by computational protein-ligand dock-
ing. Structural changes in the binding pocket and the catalytic
triad of the protease were characterized by molecular dynam-
ics simulations of T54A/S mutants and rotamer analysis of
V36A/G/L/M side chain conformations. A residue-based net-
work of non-covalent interactions was constructed to investi-
gate molecular mechanisms of drug resistance. Experimental
data are provided for the V36G mutant to corroborate our
findings. The last section comprises a sequence analysis of
HCV genotypes and their polymorphisms with respect to the
mutational sites discussed in this study.
Analysis of NS3-4A protease structures and ligand 
binding modes
The mutated positions V36 and T54 are buried in the protease
domain of NS3-4A in the two β-strands β1 and β3 of an anti-
parallel β-sheet (Figure 2). T54 is at the very end of the strand
β3, next to a loop directly involved in the ligand binding cavity
at the protein surface. The side chains of V36 and T54 point
towards each other. We identified a buried cavity between
V36 and T54 and calculated the cavity size in the wild-type
and in the T54A mutant. Comparison of the volumetric data
for both cavities indicates no significant difference in size.
Both mutated sites are located close to a hydrophobic cavity
of the ligand binding pocket at the protein surface (Figure 2).
Superposition of alternative experimental structures of NS3-
4A was used to determine conformational changes of the pro-
tein structure and the binding modes of different co-crystal-
lized protease ligands. The backbone is conserved in most
parts. The three residues Q41, I132 and D168 near the ligand
binding site show considerable variability in their side chainhttp://genomebiology.com/2008/9/1/R16 Genome Biology 2008,     Volume 9, Issue 1, Article R16       Welsch et al. R16.3
Genome Biology 2008, 9:R16
Molecular structures of the NS3-4A serine protease inhibitors VX-950 (telaprevir) and SCH 503034 (boceprevir) as well as of the co-crystallized protease  ligands CPX and SCH 446211 Figure 1
Molecular structures of the NS3-4A serine protease inhibitors VX-950 (telaprevir) and SCH 503034 (boceprevir) as well as of the co-crystallized protease 
ligands CPX and SCH 446211. The P1 to P4 and P'1 to P'2 groups are numbered according to the nomenclature of Schechter and Berger [61]. Residues 
surrounding a cleavage site are designated from the amino- to carboxyl-terminus, that is, P4-P3-P2-P1 P'1-P'2-P'3-P'4, with the scissile bond between P1 and 
P'1. They are annotated only for SCH 446211.
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conformations. In addition, the catalytic residue H57 adopts a
different side-chain conformation when the protease binds an
inhibitor derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxy-
lic acid (PDB entry 2F9U [29]). We identified an experimental
protease structure (PDB entry 2FM2 [30]) containing the SCH
446211 ketoamide inhibitor (SCH 6), which is similar to VX-
950. The ligand scaffolds of these two inhibitors differ only in
the region of the scissile bond and the P'1 group (Figure 1).
Therefore, a similar binding mode for VX-950 and SCH 446211
is expected [31]. In addition, the PDB entry 1RTL [32] includes
a protease bound to the ligand CPX (N-[(2R,3S)-1-((2S)-2-
{[(cyclopentylamino)carbonyl]amino}-3-methylbutanoyl)-2-
(1-formyl-1-cyclobutyl)pyrrolidinyl]cyclopropanecarboxam-
ide). CPX and the VX-950 compound include a cyclopropyl
group at an equivalent position (Figure 1). The cyclopropyl
group of the CPX ligand is tightly bound into a narrow hydro-
phobic cavity at the protease surface of 1RTL (Figure 2). Pre-
sumably, the cyclopropyl group of VX-950 is oriented towards
the same hydrophobic cavity.
We docked the compound VX-950 to the NS3-4A protease to
determine its conformation in the ligand binding pocket (Fig-
ure 3). FlexX generated nine different placements of VX-950,
and the top-ranking placement exhibits a binding mode com-
parable to that of the 2FM2 ligand SCH 446211. As expected
from the structure analysis detailed above, the VX-950 cyclo-
propyl group is placed towards the hydrophobic cavity in the
ligand binding pocket, similar to the placement of the cyclo-
propyl group of CPX in 1RTL. The cyclopropyl group is buried
in the surface cavity and faces towards the aromatic ring of
F43. The binding modes of the 1RTL and 2FM2 ligands CPX
and SCH 446211, respectively, are given in Figure S1 in Addi-
tional data file 1.
A two-dimensional network of non-covalent, hydrogen bonds
(H-bonds) and van der Waals, interactions between amino
acids (Figure S2 in Additional data file 1) was generated based
on the PDB structure model 1RTL of the protease NS3-4A. We
selected a subset of the complete network, including the cata-
lytic triad of the protease NS3-4A, the mutational sites V36,
T54, R155 and A156, and other residues involved in interac-
tions with VX-950, CPX and SCH 446211 (Figure 4). The lig-
and CPX forms interactions with the cyclopropyl group by
van der Waals interactions at Q41, F43, H57 and G58 (Figure
4), but the ligand SCH 446211 interacts only with Q41 and
H57, but not F43 and G58. No interaction can be observed
with the mutational sites V36 and T54 in the case of the ligand
CPX and SCH 446211 (Figure 4). The docking result for VX-
950 predicts van der Waals interactions of the cyclopropyl
group with Q41, F43 and H57. Protein-ligand interactions for
the ligands CPX and SCH 446211 as well as for VX-950 dock-
ing are summarized in the list included in Figure 4.
Mutations at position T54
T54 is located at the very end of the β-strand β3 (Figure 2),
which belongs to an anti-parallel β-sheet. The hydroxyl group
of the T54 side chain is involved in the formation of two H-
bonds with residues V55 and L44 in the strands β3 and β1,
respectively (Figure 5a). In the wild-type structure, the tip of
the β3-strand turns slightly away from the neighboring β1-
strand (Figure 5a) in the same β-sheet. The distance in the
native protein structure between the backbone H-bond donor
and acceptor in L44 and V55 of the strands β1 and β3 is too
large (4.69 Å) to be bridged by a single H-bond. Two H-bonds
from the threonine side chain at position 54 bridge the two
strands and thereby stabilize the local β-sheet conformation.
T54S is a conservative substitution with a preserved hydroxyl
group and identical H-bonding pattern, whereas T54A is a
non-conservative mutation. The missing hydroxyl group in
T54A is expected to have an impact on the H-bonding pattern
and the local β-sheet conformation, possibly impacting inhib-
itor binding.
The same expectation holds for the conformation of the
neighboring loop consisting of the residues V55, Y56, H57
and G58. T54 is located next to this loop structure (Figures 2
and 5b), which is involved in shaping the protease surface and
the cavity accommodating the cyclopropyl group. Local con-
formational changes upon mutation at T54, particularly
T54A, are expected to have an impact on the succeeding loop,
Table 1
Enzymatic in vitro drug resistance data for telaprevir (VX-950)
IC50 mean (nM) IC50 range (nM) IC50 (fold changes)
HCV genotype 1a 70 - -
V36A/G/L/M 226 110-444 1.7-6.9
T54S 120 - 1.9
T54A 749 - 11.7
R155G/I/K/L/M/S/T 538 275-1,050 4.3-16.4
A156I/T/V 29,800 12,500-50,000 195-781
A156S 1,400 - 21.9
Enzymatic in vitro resistance data for VX-950 (mean IC50 values, IC50 range and IC50 fold changes) are compared to the reference strain HCV-H, 
genotype 1a (UniProtKB accession number P27958) and are shown for VX-950 inhibition of wild-type and mutant NS3-4A proteases (V36, T54, 
R155 and A156) [19,26,28].http://genomebiology.com/2008/9/1/R16 Genome Biology 2008,     Volume 9, Issue 1, Article R16       Welsch et al. R16.5
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affecting the cavity conformation and the residues Q41, F43
and H57 involved in direct interactions with the VX-950
cyclopropyl group (Figure 4).
We did not observe non-covalent interactions between T54
and the catalytic triad residues consisting of H57, D81 and
S139. However, catalytic triad residues interact directly with
residue V55, which follows T54. In addition, residues T54 and
V55 interact via an H-bond (Figure 5c). Therefore, T54 inter-
acts with each of the catalytic residues indirectly via V55.
Together with the structural changes found in the ligand
binding site (see 'Molecular dynamics simulations of T54
mutant structures' described below), a potential impact of the
mutation T54A on catalytic residues might explain effects on
the catalytic activity of the protease NS3-4A. We found no
direct non-covalent interaction of T54 with G137, a residue of
the oxyanion hole. Nevertheless, an indirect effect could
occur via residue L44 and two edges (see network in Figure
4).
NS3-4A protease domain of PDB structure 1RTL with co-crystallized ligand CPX (yellow) [32] and a second ligand, SCH 446211 (light blue), taken from  the superimposed PDB structure 2FM2 [30] Figure 2
NS3-4A protease domain of PDB structure 1RTL with co-crystallized ligand CPX (yellow) [32] and a second ligand, SCH 446211 (light blue), taken from 
the superimposed PDB structure 2FM2 [30]. The protease binding pocket from structure 1RTL is shown as a transparent surface patch. The residues V36 
and T54 are depicted as stick-and-ball models, located in the parallel β-strands β1 and β3 of an anti-parallel β-sheet (dark blue).
V36
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β3Genome Biology 2008, 9:R16
http://genomebiology.com/2008/9/1/R16 Genome Biology 2008,     Volume 9, Issue 1, Article R16       Welsch et al. R16.6
Figure 3 (see legend on next page)
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Molecular dynamics simulations of T54 mutant 
structures
We investigated conformational changes upon mutation at
T54 by molecular dynamics simulations. Simulations were
performed for the wild-type structure 2FM2 and the mutants
T54A and T54S (see Materials and methods). We predomi-
nantly observed two effects. First, both mutations T54A and
T54S yield considerably decreased side chain volumes in
comparison to the wild-type structure, leading to joint side
chain rearrangements of the residues V55, H57 and S139 sur-
rounding residue T54 (Figure 6a). The changes observed in
side chain orientation are more pronounced for the T54A
mutant than for the T54S mutant. During the observed rear-
rangements, the side chain of V55 is rotated, allowing the
five-membered ring of H57 to rotate and the side chain of
S139 to rotate towards the protein interior. This observation
is in agreement with the results of our analysis of the residue
interaction network (Figure 5c), which shows the relevance of
V55 regarding the structural integrity of the catalytic site of
the protease. This finding can readily be explained by the
smaller size of the side chain of alanine in contrast to serine
or threonine and by the reduced capability of alanine to form
H-bonds. Notably, the observed relevance of the L44-T54-
V55 H-bonding pattern for the impact of mutations at T54 is
in good agreement with our findings from studying the resi-
due interaction network (Figure 5a). Another observed effect
is a change in the depth of the binding pocket between the
wild-type structure and the T54A mutant, which possibly has
an impact on protease-ligand interactions. This depth change
is noticeable for the region formed by the five residues, Q41,
T42, F43, G58 and A59. Residues Q41, T42 and F43 are con-
nected to residue T54 via van der Waals interactions. F43
interacts directly with T54, whereas residues Q41 and T42
interact indirectly with it (Figure 6b). The aromatic ring of
F43 is located directly next to the side chain of T54. Due to the
considerable decrease in side chain volume of the T54A
mutant and its hydrophobicity, this aromatic ring moves
towards the protein interior of the mutant structure (Figure
6a). In addition, L44 forms an H-bond with the hydroxyl
group of the side chains of both T54 and S54 (Figures 5a and
6b) and establishes van der Waals interactions with residues
Q41 to F43. In contrast, this H-bond does not exist in the
T54A mutant. This missing H-bond to L44 and the change in
side chain orientation of F43 lead to a shallower cyclopropyl
binding pocket in the T54A mutant compared to the wild-type
structure; no such effect is observed for the T54S mutation.
In general, the surface and hydrophobic cavity are shallower
in the mutant structure T54A than in the wild type, but this is
not the case for T54S. Figure 6c illustrates the decreased vol-
ume of the cavity using the surface of the mutant structures,
which covers the surface of the wild-type structure in the
cyclopropyl binding pocket. In summary, the molecular
dynamics simulations for T54A/S mutant structures corrobo-
rate the previous analysis of the residue interaction network.
Both studies suggest a conformation change at the binding
site for the T54 mutants.
Mutations at position V36
Both in the three-dimensional structure and within the resi-
due interaction network, V36 is more distant than T54 from
the residues (Q41, F43 and H57) involved in interactions with
the cyclopropyl group of VX-950 (Figure 7). In the interaction
network, we identified two types of van der Waals interac-
tions between V36 and F43, backbone-side chain and side
chain-side chain. In particular, F43 is directly involved in
forming the hydrophobic cavity and in interactions with the
cyclopropyl group. F43 is also linked by two edges to Q41.
The network distance between V36 and the catalytic residues
is larger than between T54 and the same residues. V36 inter-
acts indirectly with S139 via a two-edge path including F43.
At least three to four edges in the network need to be tra-
versed to reach the other catalytic residues H57 or D81. No
direct non-covalent interaction is present between V36 and
any of the catalytic residues H57, D81 or S139. Similarly,
there is no direct non-covalent interaction between V36 and
the oxyanion hole at G137. An indirect interaction of V36 with
G137 is possible via two edges (see network in Figure 4).
Rotamer analysis of V36 mutations
We predicted side chain conformations of the mutated resi-
dues A/G/L/M at position V36 using IRECS [33]. Figure 8
illustrates potential side chain conformations for the wild-
type residue V36 and the A/G/L/M mutants. Our analysis
reveals that: all side chains are oriented towards the protein
center and away from the ligand-binding pocket; and one Cγ
atom in the side chain of the mutant residues and a second Cγ
atom of the wild-type V36 point towards the aromatic ring of
F43. The second Cγ carbon of V36 is engaged in van der Waals
interactions with the aromatic ring of F43. There is no equiv-
alent to the second Cγ carbon in the V36 mutants A/G/L/M.
Therefore, a slight displacement of the F43 side chain
towards the protein interior can be expected in the mutant
structures relative to the wild-type structure. In particular,
the residue interaction network in Figure 7 demonstrates that
changes at F43 can impact the conformation of the catalytic
VX-950 protein-ligand binding Figure 3 (see previous page)
VX-950 protein-ligand binding. (a) Surface representation of the NS3-4A protease binding pocket (PDB entry 1RTL) with the docked VX-950 compound. 
VX-950 is covalently bound to S139. The cyclopropyl group is oriented towards a hydrophobic cavity. The surface of the protein was colored with the 
vacuum electrostatics function of PyMOL. Charges are computed with the Amber 99 force field and projected on the protein surface, whereas colored 
patches (red = positive, blue = negative) denote polar regions and white patches apolar protein regions. (b) MOE plot for interactions of the protease 
with the VX-950 compound. The legend is at the bottom.Genome Biology 2008, 9:R16
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residue S139 and of Q41 and its binding to the cyclopropyl
group of VX-950.
In vitro analysis of the V36G resistance mutation using 
an HCV replicon-assay
Based upon our previous analysis, we performed a compari-
son of antiviral efficacies for the two protease inhibitors VX-
950 and SCH 503034. Only the SCH 503034 inhibitor is
lacking the cyclopropyl group (Figure 1). We used a wild-type
HCV replicon assay (genotype 1b) and an assay harboring the
V36G mutant for in vitro testing. Detailed information on
experimental procedures is given in Materials and methods.
We found that the SCH 503034 inhibitor is efficient on the
V36G mutant with effective suppression of viral RNA titers
and a mean IC50 value clearly below 5 μM. In contrast, VX-
950 was less effective in the V36G mutant replicon assay, with
an IC50 value of about 5 μM. In comparison to the wild-type
replicon assay, viral suppression was considerably delayed
only for VX-950 in the V36G mutant assay. SCH 503034 was
nearly equally effective in viral suppression for both the V36G
mutant assay and the wild-type assay (Figure S3 in Additional
data file 1).
Comparison of HCV genotypes
We analyzed residues in the cyclopropyl binding cavity of the
NS3-4A protease and at the mutational sites V36 and T54
with respect to their inter-genotype variability based on the
recent HCV genotype nomenclature [34]. The cavity-forming
residues Q41, T42, F43, H57, G58 and A59 are strongly con-
served throughout the investigated HCV sequences. We
observed a conservative T42S polymorphism in about 61% of
the sequences. The only non-conservative polymorphisms
H57Y and A59P are found in genotypes 6h and 6a, respec-
tively. These results point to overall similar shapes and phys-
icochemical properties of the cavities in NS3 protease domain
structures, resulting in comparable binding modes of the VX-
950 cyclopropyl group for all HCV genotypes investigated.
Regarding the mutational sites V36 and T54, we found a con-
servative V36L polymorphism in about 67% of all sequences,
with L36 in genotypes 1b, 2, 3, 4, 5 and 6c/g. In contrast, T54
is strictly conserved in all HCV genotypes (Figure 9). Consid-
ering our rotamer analysis and the importance of the number
of side chain Cγ atoms at position 36 for the F43 side chain
conformation, we can conclude that HCV sequences with L36
(with only one Cγ atom) should be less susceptible to drug
resistance mutations at this site, especially the clinically more
relevant HCV genotypes 1b, 2 and 3. F43 seems to be impor-
tant for resistance development at V36 and T54 and has a
conservation of 100%. L44 was found to be involved in mech-
anisms of drug resistance at T54 and showed a conservation
of 94%. A conservative L44V polymorphism was found in
HCV genotype 6a. Position 55, which was supposed to be
responsible for impaired catalytic activity in T54 protease
mutants, was conserved in 94%. A conservative V55L poly-
morphism was found in HCV genotype 5a.
Discussion
Our results indicate that the cyclopropyl group of VX-950 is
oriented towards a hydrophobic cavity in the binding pocket
of the HCV protease NS3-4A. The cyclopropyl binding mode
and the geometry of the cavity appear to play an essential role
in the development of drug resistance by mutants at positions
V36 and T54. The residue T54 lies in an anti-parallel β-sheet,
which is followed by a loop structure involved in shaping the
hydrophobic cavity. We expect a larger impact of T54A than
T54S on the β-sheet conformation due to the affected H-bond
formation.
Molecular dynamics simulations of T54A/S mutant struc-
tures support our interpretation. We observed more pro-
nounced structural changes in the case of T54A compared to
T54S, which impact the binding pocket, particularly at the
hydrophobic cavity that accommodates the cyclopropyl
group. We also observed a reduced depth of the cyclopropyl
binding cavity for the T54A mutant structure. In vitro data for
T54A revealed an 11.7-fold increase of IC50, whereas T54S
showed only a minimal level of drug resistance, with a 1.9-fold
increase in IC50 (Table 1) [19,26-28]. We suppose that the
minor impact on the protease structure and the less compro-
mised VX-950 binding in the case of T54S results in low-level
drug resistance, in contrast to T54A with higher drug
resistance levels. Furthermore, we analyzed potential molec-
ular mechanisms affecting catalytic residues of the NS3-4A
protease and the implications for viral replication efficacy. A
network of non-covalent residue interactions demonstrated
possible effects of T54 mutants not only on the ligand binding
site, but also on the catalytic residues. This is in agreement
with results of molecular dynamics simulations upon T54A/S
Network of non-covalent residue interactions for the NS3-4A protease and the corresponding list of protein-ligand interactions Figure 4 (see previous page)
Network of non-covalent residue interactions for the NS3-4A protease and the corresponding list of protein-ligand interactions. (a) Network analysis of 
non-covalent residue interactions for the NS3-4A protease (PDB entry 1RTL). Nodes represent residues and colored edges represent different types of 
interactions: van der Waals interactions, backbone-side chain (blue), side chain-side chain (red); H-bond interactions, backbone-side chain (green), side 
chain-side chain (orange). Protein-ligand interactions for the 1RTL and 2FM2 ligands CPX and SCH 446211, respectively, as well as for VX-950 are tagged 
by brown Arabic numerals above each residue node (see (b)). Catalytic residues are yellow and the mutated residues are blue (V36), red (T54) and grey 
(R155, A156). (b) List of van der Waals interactions (vdW), H-bonds (HB) and covalent bonds (CB) for the 1RTL and 2FM2 ligands CPX and SCH 446211, 
respectively, and the VX-950 ligand docking result. Each dot or square represents one interaction of the ligand with an amino acid of the NS3-4A protease, 
and dots indicate interactions with the cyclopropyl group. Brown Arabic numerals refer to protein-ligand interactions in the network of non-covalent 
interactions (a).Genome Biology 2008, 9:R16
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mutation and underlines the considerable negative influence
of T54 mutants on the protease catalytic activity.
We found V36 to be located farther away from the hydropho-
bic cavity than T54, both in the three-dimensional structure
and in the residue interaction network derived from the NS3
protease structure. We observed non-covalent interactions of
the wild-type V36 with a residue that shapes the hydrophobic
cavity. The mutations V36A/G/L/M allow a displacement of
the side chain of this residue, thereby changing the shape of
the cavity. Thus, the V36 mutants affect only the shape of the
cyclopropyl binding cavity, which is in agreement with the
corresponding low-level drug resistance and weak IC50 fold
changes of only 1.7 to 6.9 (Table 1) for V36A/L/M single
mutations [19,26-28]. We conjecture that the binding
affinities of the VX-950 compound are modified only margin-
ally, which is consistent with the low-level drug resistance.
The residue V36 and its mutants are only of minor relevance
for the protease catalytic activity. In comparison with T54, we
observed lower network connectivity and larger distance
from catalytic triad residues in the network for the V36 node.
This may explain why V36 mutants have been observed in all
breakthrough patients and more frequently in follow-up
sequencing data than T54 mutants, which indicates greater
protease enzymatic activities and better viral replication effi-
cacies [18,19,26-28]. After withdrawal of VX-950, V36
mutants remained at a fairly steady frequency in HCV quasis-
pecies populations, most probably due to an only slightly
decreased viral replication rate and a low-level drug resist-
ance [18,19,26-28].
Moreover, we performed a comprehensive comparison of
NS3 protease sequences for all HCV genotypes. We found
only minor variability at the mutational sites and residue
positions investigated in this study. The clinically most rele-
vant HCV genotypes 1, 2 and 3 are particularly similar in con-
trast to other genotypes. Altogether, we assume closely
related molecular resistance mechanisms for all HCV geno-
types when treated with VX-950 or compounds with a similar
scaffold.
Conclusion
We identified a narrow hydrophobic cavity in the binding
pocket of the protease NS3-4A accommodating the cyclopro-
pyl group of VX-950 (telaprevir). Mutations at V36 and T54
are expected to affect local conformation and the geometry of
this cavity, which explains the observed drug resistance. We
used a structural network of non-covalent interactions
between NS3 protease residues to investigate molecular
effects underlying drug resistance. Notably, this novel meth-
odological approach is of general applicability for many stud-
ies of protein structure and function. In our work, the residue
interaction network allowed the identification of key mecha-
nisms responsible for conformational changes in the ligand
binding pocket and hydrophobic cavity as well as for func-
tional effects on the protease catalytic residues. Molecular
dynamics simulations and rotamer analysis support our find-
ings well. Additionally, we performed experimental inhibitor
studies with VX-950 and SCH 503034 in a mutant HCV rep-
licon assay, which corroborated our results.
Based on the present work, we conclude that add-on or switch
to complementary protease inhibitors, possessing no cyclo-
propyl or similar group in an equivalent position as in VX-
950, might help to avoid cross-resistance during viral break-
through and follow-up. Therefore, we suggest further experi-
ments to examine our observations. NS3 protease mutants
could be tested for their antiviral efficacy and compromised
viral replication. Based upon our findings, it would be of
interest to compare the efficacy of VX-950 against that of
SCH 503034 for other V36 and T54 mutants. Apart from that,
crystal structure information would be desirable for mutant
structures with co-complexed drugs like VX-950 to confirm
our computational analysis.
Materials and methods
Analysis of experimental structural models of NS3-4A
Alternative experimental structure models of the HCV pro-
tease NS3 were compared based on the differences of the
intramolecular distances using the backbone carbon alpha
(Cα) atoms and the geometric centers of the side chain atoms
[35]. In total, 37 experimental models available in the PDB
[13,14] were analyzed, including five structure models lacking
NS4A. The 32 different structure models of the NS3-4A pro-
tease were superimposed for further analysis, excluding the
five models without NS4A due to major conformational dif-
ferences. Invariant structural regions were identified and
superimposed [35]. Multiple structure models determined by
Structure and network analysis of non-covalent residue interactions for T54 Figure 5 (see following page)
Structure and network analysis of non-covalent residue interactions for T54. Left column: visualization of the NS3-4A protease structure and surface of 
the binding pocket of 1RTL with co-crystallized ligands taken from two superimposed PDB structures: 1RTL with ligand CPX (yellow) and 2FM2 with 
ligand SCH 446211 (light blue). Right column: corresponding network analysis of non-covalent residue interactions for T54 mutants. Residues presumed to 
interact with the cyclopropyl group of VX-950 are indicated by black dots. Nodes represent residues and colored edges represent different types of 
interactions (see Figure 4): van der Waals interactions, backbone-side chain (blue), side chain-side chain (red); H-bond interactions, backbone-side chain 
(green), side chain-side chain (orange). (a) Anti-parallel β-sheet and H-bond interactions of T54 with L44 and V55 (yellow). H-bonds are shown as cyan 
dotted lines and corresponding distances printed in cyan. (b) Loop-forming residues (orange) and hydrophobic pocket conformation. (c) Impact of T54 
mutants on the catalytic triad via the node V55 (purple).http://genomebiology.com/2008/9/1/R16 Genome Biology 2008,     Volume 9, Issue 1, Article R16       Welsch et al. R16.11
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X-ray crystallography are normally available from each PDB
entry because it includes more than one protease domain in
the asymmetric unit. We used PyMOL [36] for the visualiza-
tion of protein structure images. Chimera [37] was used for
the calculation of buried cavities within the NS3-4A protease
(PDB entry 2FM2) and the derived mutant structures.
MD simulations of T54 mutants Figure 6
MD simulations of T54 mutants. (a) Three-dimensional structure analysis of the NS3-4A protease binding pocket taken from the equilibrated structures of 
the MD simulations of the wild-type (PDB entry 2FM2) and the T54A and T54S mutants (all with ligand SCH 446211). The wild-type protease structure is 
shown in green and its ligand in yellow. The mutants T54A and T54S are colored red and blue, respectively, and the corresponding ligands white. Part of 
the surface of the T54A mutant structure is shown in wireframe representation. For the sake of clarity, we have not included the surfaces of the wild-type 
protein and the T54S mutant structure. The side chains of the residues H57 and S139 in the wild-type structure extend out of the surface of the mutant 
structure. One of the hydroxyl groups of the SCH 446211 ligand in the wild-type structure clashes with the mutant's surface. Thus, in the mutated 
structures, this group is rotated by about 90 degrees to the upper right of the inhibitor. (b) Structural changes observed by MD simulations are reflected 
by the corresponding network of non-covalent residue interactions. Important conformational changes occur at L44 and V55, which do not directly 
interact with the ligand. Only H57 and S139 contact the ligand, and H57 forms direct interactions with the cyclopropyl group of VX-950. Nodes in the 
network are highlighted according to the MD simulation results (for details, see legend of Figure 5). (c) Protein surface of the binding pocket for the wild-
type protease structure (green) with the ligand SCH 446211 (yellow) in comparison to the T54A mutant structure (red). The changes in the surface 
(circled in black) correspond to considerable side chain movements as discussed in (a). (d) Protein surface of the binding pocket for the wild-type protease 
structure (green) with the ligand SCH 446211 (yellow) in comparison to the T54S mutant structure (blue). The changes in the surface area (circled in 
black) correspond to considerable side chain movements as described in (a).
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Protein-ligand docking
The protein-ligand docking of VX-950 was performed using
PDB entry 1RTL of the protease NS3-4A. The binding pocket
was defined as a subset of all residues that have at least one
atom closer than 6.5 Å to any atom of the 1RTL ligand. The
ScreenScore [38] parameterization of the docking program
FlexX [39] was applied to account for the mainly hydrophobic
nature of VX-950 and to compensate small-scale induced-fit
effects because ScreenScore uses a softer consensus scoring
function than the standard FlexX does. The chemical
structure of the ligand VX-950 (Figure 1) was drawn with
MDL ISIS/Draw [40]. The three-dimensional structure was
derived by energy minimization with MMFF94. The cyclopro-
pyl group of VX-950 was selected as the base fragment of
FlexX to achieve a high sampling rate on this group. First, VX-
950 was docked into the binding pocket without specifying a
covalent bond. FlexX automatically places VX-950 in a non-
covalent binding mode so that the cyclopropyl group is placed
in the same hydrophobic region as the CPX ligand in 1RTL
and so the ketone oxygen is nearby the S139 side chain. Next,
we fixed the covalent bond and relaxed the structure of VX-
950 using a 100-step energy minimization. We chose this
two-step setup to ensure that the docking is not biased by the
geometrical constraints of a predefined covalent bond. The
covalent bonding was observed for analogous ketoamide
inhibitors [25] and ketoacid inhibitors [12]. We used MOE
(Molecular Operating Environment) [41] to visualize ligand
interaction diagrams for 1RTL and 2FM2 ligands and PyMOL
[36] for the visualization of the VX-950 docking results.
Network of non-covalent interactions
In the following, the term interaction denotes non-covalent
interactions. The non-covalent H-bond and van der Waals
interactions between amino acids were identified in PDB
entry 1RTL and represented as a two-dimensional network.
We used the WHAT IF web interface [42,43] to identify H-
bonds and van der Waals interactions between residues. The
network was visualized in Cytoscape [44]. LIGPLOT [45] was
additionally applied to identify H-bonds and van der Waals
interactions of the ligand with amino acids of the protease
NS3-4A. The local connectivity of each residue was calculated
as the number of its interactions using the Cytoscape plugin
NetworkAnalyzer [46,47], which suggested residues of func-
tional importance in the interaction network. Distances
between residue nodes were computed by NetworkAnalyzer
as the minimum number of interaction edges connecting two
nodes.
Rotamer analysis and side chain orientation
We predicted side chain conformations of the mutated resi-
dues V36A/G/L/M with the tool IRECS (Iterated Restriction
of Conformational Space) [33]. IRECS analyses ensembles of
possible rotameric states of side chains and subsequently fil-
ters out states with unlikely interaction patterns with the
backbone and other side chains.
Molecular dynamics simulations
Molecular dynamics (MD) simulations were performed for
the wild-type structure of the NS3-4A protease and the
mutants T54A and T54S using the program GROMACS3.3
[48]. Regarding the mutant structures, the wild-type struc-
ture (PDB entry 2FM2) was used and the corresponding side
chain (T54) was mutated using the tool IRECS [33]. The orig-
inal ligand SCH 446211 from 2FM2 was used for the simula-
tions. This choice was based on the fact that the goal of the
simulations was to evaluate the influence of the mutations on
the protein structure in general, which should be the same
regardless of the bound ligand and should not depend on the
Visualization of the NS3-4A protease binding pocket (left) and the corresponding network of non-covalent residue interactions in the neighborhood of F43  (right) Figure 7
Visualization of the NS3-4A protease binding pocket (left) and the corresponding network of non-covalent residue interactions in the neighborhood of F43 
(right). For details, see the legend of Figure 5.
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binding of a specific ligand. Thus, we used the original exper-
imental ligand SCH 446211 in order to avoid potential arti-
facts originating from docking inaccuracies in our simulation.
The analysis of the simulation results was based on the final
structures of the simulations after equilibration. For the sim-
ulations, the GROMOS96 force field [49] and the SPC water
model were used, applying periodic boundary conditions. The
long-range non-bonded interactions were treated by particle-
mesh Ewald summation, and a time step of 2 fs was used.
Throughout the simulations, the bond lengths were con-
strained to ideal values using the LINCS procedure [50]. The
system was heated from 0 to 300 K over 120 ps, and the sim-
ulations were then continued at 300 K and at a constant pres-
sure of 1 atm for 2 ns. The temperature and pressure were
maintained by weak coupling to an external bath with a tem-
perature coupling relaxation time of 0.1 ps and a compressi-
bility of 4.5·10-5  [51]. For the analysis of MD simulation
results, the average structures of the protease-inhibitor com-
plexes of the last 100 ps of the simulations were used, super-
imposing backbone Cα  atoms. On the basis of these
structures, the conformations of the residues in the binding
pocket and the pocket surface were analyzed. The tool VMD
[52] was applied for the visualization of simulated protease-
ligand structures.
Rotameric states and conformational differences for V36 mutants A/G/L/M computed with IRECS using the PDB entry 1RTL Figure 8
Rotameric states and conformational differences for V36 mutants A/G/L/M computed with IRECS using the PDB entry 1RTL. The figure illustrates the 
relative position of mutant side chains (light grey) and the wild-type residue V36 (blue). The important carbon atoms of the side chains are indicated as Cα, 
Cβ and Cγ. Protein backbone changes are depicted in black. The contribution of F43 to the hydrophobic cavity conformation and the cyclopropyl binding 
pocket is illustrated by means of a transparent surface patch.
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Multiple sequence analysis
Sequences of the different HCV variants of the NS3-4A pro-
tease were retrieved from the UniProtKB database [53,54].
HCV genotypes are named according to a recent consensus
proposal for a unified system of HCV genotype nomenclature
[34]. The UniProtKB accession numbers of the sequences
reported in this paper are given in Table S1 in Additional data
file 1. A multiple sequence alignment (Figure 9) of the NS3-4A
protease domain was computed using MUSCLE [55] and
subsequently improved by minor manual modifications using
the SEAVIEW alignment editor [56]. The secondary structure
assignment to the PDB structure 1DY8 was taken from the
DSSP database [57,58]. The sequence alignment figure was
illustrated using GeneDoc [59]. Residue numbering in the
Multiple alignment of NS3 protease sequences for different HCV genotypes Figure 9
Multiple alignment of NS3 protease sequences for different HCV genotypes. UniProtKB accession numbers are given in Table S1 in Additional data file 1. 
The aligned sequences contain amino acids 16 to 176 according to the PDB entry 1DY8 (UniProtKB accession number P26662). The DSSP secondary 
structure assignment for 1DY8 is illustrated at the top of the alignment with curled lines for α-helices and arrows for β-strands. The catalytic triad 
consisting of H57, D81 and S139 and a zinc finger formed by C97, C99 and C145 is indicated at the bottom of the alignment by orange and yellow squares, 
respectively. The binding cavity for the cyclopropyl group of the VX-950 compound and CPX ligand is marked by purple squares. Text labels annotate 
different sites of drug resistance mutations (V36, T54, R155, A156) for VX-950. Amino acids are shaded in different grey levels according to their 
physicochemical properties: aliphatic (A/C/G/I/L/M/N/Q/V), black (white letters); aromatic (F/W/Y), white (black letters); cyclic (P), light grey (white 
letters); basic (H/K/R), grey (white letters); acidic (D/E), dark grey (white letters). Amino acids with conformational changes described in the paper are 
framed by green boxes.
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manuscript is according to HCV genotype 1b, PDB entry
1DY8.
In vitro IC50 determination of mutant NS3-4A 
proteases
Compounds
VX-950 was synthesized by the European Network of Excel-
lence for Viral Resistance in Hepatitis C (viRgil, Drugpharm),
dissolved in dimethyl sulfoxide as a 6.6 mM solution. SCH
503034 was synthesized by Schering-Plough Corporation
(Kenilworth, NJ, USA), dissolved in dimethyl sulfoxide as a 19
mM solution. Both compounds were stored at 4°C.
Plasmids and in vitro RNA transcription
The plasmid pFKI389neo/NS3-3'/ET contains HCV subge-
nomic replicon sequences derived from HCV genotype 1b and
an upstream T7 promoter for in vitro RNA synthesis. The
point mutation was generated with the QuikChange II XL
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA). The plasmid was linearized with ScaI and purified by
phenol chloroform extraction. The linearized and purified
plasmid was transcribed by using a T7 RNA polymerase
(Promega, Madison, WI, USA) according to the
manufacturer's instructions. All of the plasmids and RNAs
were checked for purity and integrity by standard procedures.
Generation of HCV replicon cell lines
Huh-7.5 cells were cultured in Dulbecco's modified Eagle's
medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing
10% fetal bovine serum (FBS; PAA Laboratories GmbH,
Pasching, Germany) and 2 mM L-glutamine. The cells were
transfected with an in vitro-transcribed subgenomic HCV
replicon RNA. The wild-type sequence was identical to that of
the pFKI389neo/NS3-3'/ET replicon [60]. Stable cells con-
taining the self-replicating HCV replicon were selected and
maintained in the presence of 750 μg of G418 (Invitrogen) per
ml and were used for HCV replicon assays.
Two-day HCV replicon assay
HCV replicon cells were plated in a 6-well plate at a density of
2 × 105 cells per well in DMEM with 10% FBS. On the follow-
ing day (24 h later), the culture medium was replaced with
DMEM containing either no compound as a control or com-
pounds serially diluted in the presence of 10% FBS and 750
μg/ml G418. After the cells were incubated with the com-
pounds for 48 h, the intracellular RNA was extracted with an
RNeasy kit (Qiagen, Valencia, CA, USA). The level of HCV
RNA was determined by a real-time quantitative reverse tran-
scription-PCR (RT-PCR) assay (Taqman) with a pair of HCV-
specific primers (5'-ACG CAG AAA GCG TCT AGC CAT-3' and
5'-TAC TCA CCG GTT CCG CAG A-3'), an HCV-specific probe
(5'-6FAM-TCC TGG AGG CTG CAC GAC ACT CA XT-PH-3),
and an ABI Prism 7000 sequence detection system (Applied
Biosystems, Foster City, CA, USA). The IC50 was defined as
the concentration of compound at which the HCV RNA level
in the replicon cells was reduced by 50%.
Abbreviations
DMEM, Dulbecco's modified Eagle's medium; FBS, fetal
bovine serum; H-bond, hydrogen bond; HCV, hepatitis C
virus; IC50, inhibitory concentration 50%; MD, molecular
dynamics; PDB, Protein Data Bank; RT-PCR, reverse
transcription-PCR.
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Additional data file 1 Supplementary figures and table Figure S1 illustrates NS3-4A protease-ligand interactions. Figure  S2 shows the complete network of non-covalent, H-bond and van  der Waals, interactions of the NS3-4A protease for the PDB entry  1RTL. Figure S3 gives results of SCH 503034 and VX-950 inhibitor  studies using an HCV V36G mutant replicon assay. Table S1 lists  HCV genotypes included into the multiple sequence alignment of  Figure 9. Click here for file
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